# Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

> **NCT00911820** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 88 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer
- Stomach Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cisplatin
- **DRUG:** Irinotecan
- **DEVICE:** Docetaxel

## Key facts

- **NCT ID:** NCT00911820
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-04
- **Final completion:** 2013-08
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-11-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911820, "Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00911820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*